Beijing Beilu Pharmaceutical (300016) - Total Assets
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) holds total assets worth CN¥3.22 Billion CNY (≈ $471.45 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Beijing Beilu Pharmaceutical to assess the company's total reinvestment commitment from operating cash flow.
Beijing Beilu Pharmaceutical - Total Assets Trend (2005–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's total assets have evolved over time, based on quarterly financial data. Explore Beijing Beilu Pharmaceutical (300016) investment intensity to see how much of total assets are deployed in long-term investments.
Beijing Beilu Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Beilu Pharmaceutical's total assets of CN¥3.22 Billion consist of 39.3% current assets and 60.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.7% |
| Accounts Receivable | CN¥178.70 Million | 6.0% |
| Inventory | CN¥362.09 Million | 12.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥160.82 Million | 5.4% |
| Goodwill | CN¥46.92 Million | 1.6% |
Asset Composition Trend (2005–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Beijing Beilu Pharmaceutical.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Beilu Pharmaceutical's current assets represent 39.3% of total assets in 2024, a decrease from 48.8% in 2005.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2024, down from 11.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 4.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 12.2% of total assets.
Beijing Beilu Pharmaceutical Competitors by Total Assets
Key competitors of Beijing Beilu Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Beijing Beilu Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 2.71 | 3.93 |
| Quick Ratio | 1.61 | 1.99 | 3.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥736.08 Million | CN¥766.36 Million | CN¥1.01 Billion |
Beijing Beilu Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Beijing Beilu Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.49 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | CN¥2.98 Billion |
| Market Capitalization | $630.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Beilu Pharmaceutical's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Beilu Pharmaceutical's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Beilu Pharmaceutical (2005–2024)
The table below shows the annual total assets of Beijing Beilu Pharmaceutical from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.98 Billion ≈ $435.71 Million |
+5.61% |
| 2023-12-31 | CN¥2.82 Billion ≈ $412.57 Million |
+0.14% |
| 2022-12-31 | CN¥2.82 Billion ≈ $412.00 Million |
-3.01% |
| 2021-12-31 | CN¥2.90 Billion ≈ $424.78 Million |
+1.94% |
| 2020-12-31 | CN¥2.85 Billion ≈ $416.69 Million |
+75.36% |
| 2019-12-31 | CN¥1.62 Billion ≈ $237.62 Million |
+26.00% |
| 2018-12-31 | CN¥1.29 Billion ≈ $188.58 Million |
+12.96% |
| 2017-12-31 | CN¥1.14 Billion ≈ $166.95 Million |
+19.33% |
| 2016-12-31 | CN¥956.09 Million ≈ $139.91 Million |
-8.95% |
| 2015-12-31 | CN¥1.05 Billion ≈ $153.65 Million |
+15.77% |
| 2014-12-31 | CN¥907.00 Million ≈ $132.72 Million |
+46.16% |
| 2013-12-31 | CN¥620.54 Million ≈ $90.80 Million |
+6.33% |
| 2012-12-31 | CN¥583.60 Million ≈ $85.40 Million |
+11.23% |
| 2011-12-31 | CN¥524.66 Million ≈ $76.77 Million |
+10.43% |
| 2010-12-31 | CN¥475.11 Million ≈ $69.52 Million |
+5.27% |
| 2009-12-31 | CN¥451.31 Million ≈ $66.04 Million |
+182.51% |
| 2008-12-31 | CN¥159.75 Million ≈ $23.38 Million |
+12.75% |
| 2007-12-31 | CN¥141.69 Million ≈ $20.73 Million |
+12.73% |
| 2006-12-31 | CN¥125.69 Million ≈ $18.39 Million |
+16.96% |
| 2005-12-31 | CN¥107.46 Million ≈ $15.72 Million |
-- |
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more